Literature DB >> 28581491

Making individualized drugs a reality.

Huub Schellekens1, Mohammed Aldosari2, Herre Talsma1, Enrico Mastrobattista1.   

Abstract

Mesh：

Year:  2017        PMID： 28581491     DOI： 10.1038/nbt.3888

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  32 in total

1.  Failing the public health--rofecoxib, Merck, and the FDA.

Authors:  Eric J Topol
Journal:  N Engl J Med       Date:  2004-10-06       Impact factor: 91.245

2.  Self-cleavable stimulus responsive tags for protein purification without chromatography.

Authors:  Xin Ge; Daniel S C Yang; Kimberly Trabbic-Carlson; Bumjoon Kim; Ashutosh Chilkoti; Carlos D M Filipe
Journal:  J Am Chem Soc       Date:  2005-08-17       Impact factor: 15.419

3.  Is your love in vain? On associations between genotypes, drug concentrations and clinical outcomes in pharmacogenomic research.

Authors:  Per Damkier
Journal:  Int J Clin Pharm       Date:  2015-07-17

4.  Two centuries of assessing drug risks.

Authors:  Jerry Avorn
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

Review 5.  Computer-Assisted Synthetic Planning: The End of the Beginning.

Authors:  Sara Szymkuć; Ewa P Gajewska; Tomasz Klucznik; Karol Molga; Piotr Dittwald; Michał Startek; Michał Bajczyk; Bartosz A Grzybowski
Journal:  Angew Chem Int Ed Engl       Date:  2016-04-08       Impact factor: 15.336

6.  Microwave-assisted synthesis of small molecules targeting the infectious diseases tuberculosis, HIV/AIDS, malaria and hepatitis C.

Authors:  Johan Gising; Luke R Odell; Mats Larhed
Journal:  Org Biomol Chem       Date:  2012-01-09       Impact factor: 3.876

7.  Towards waste free organic synthesis using nanostructured hybrid silicas.

Authors:  Rosaria Ciriminna; Laura M Ilharco; Valerica Pandarus; Alexandra Fidalgo; François Béland; Mario Pagliaro
Journal:  Nanoscale       Date:  2014-06-21       Impact factor: 7.790

8.  [After the TGN1412 incident. Principles for assessment of first-in-man trials with monoclonal antibodies by the Paul Ehrlich Institute].

Authors:  C K Schneider; U Kalinke
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2007-10       Impact factor: 1.513

Review 9.  Epoetin-associated pure red cell aplasia: past, present, and future considerations.

Authors:  June M McKoy; Robin E Stonecash; Denis Cournoyer; Jerome Rossert; Allen R Nissenson; Dennis W Raisch; Nicole Casadevall; Charles L Bennett
Journal:  Transfusion       Date:  2008-05-14       Impact factor: 3.157

10.  The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development.

Authors:  P A Patten; H Schellekens
Journal:  Dev Biol (Basel)       Date:  2003
View more
  12 in total

1.  Erratum: Making individualized drugs a reality.

Authors:  Huub Schellekens; Mohammed Aldosari; Herre Talsma; Enrico Mastrobattista
Journal:  Nat Biotechnol       Date:  2017-08-08       Impact factor: 54.908

2.  Artificial Intelligence and Personalized Medicine.

Authors:  Nicholas J Schork
Journal:  Cancer Treat Res       Date:  2019

Review 3.  Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.

Authors:  Qingxin Mu; Jesse Yu; Lisa A McConnachie; John C Kraft; Yu Gao; Gaurav K Gulati; Rodney J Y Ho
Journal:  J Drug Target       Date:  2018-01-10       Impact factor: 5.121

Review 4.  Strategies for Testing Intervention Matching Schemes in Cancer.

Authors:  Nicholas J Schork; Laura H Goetz; James Lowey; Jeffrey Trent
Journal:  Clin Pharmacol Ther       Date:  2020-07-24       Impact factor: 6.875

Review 5.  Compounded medication for patients with rare diseases.

Authors:  Marc Dooms; Maria Carvalho
Journal:  Orphanet J Rare Dis       Date:  2018-01-04       Impact factor: 4.123

Review 6.  Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics.

Authors:  Yihua Bruce Yu; Katharine T Briggs; Marc B Taraban; Robert G Brinson; John P Marino
Journal:  Pharm Res       Date:  2021-02-08       Impact factor: 4.200

7.  We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis.

Authors:  Gaëlle Krikorian; Els Torreele
Journal:  Health Hum Rights       Date:  2021-06

8.  A perspective on multi-target drug discovery and design for complex diseases.

Authors:  Rona R Ramsay; Marija R Popovic-Nikolic; Katarina Nikolic; Elisa Uliassi; Maria Laura Bolognesi
Journal:  Clin Transl Med       Date:  2018-01-17

9.  Rapid recombinant protein expression in cell-free extracts from human blood.

Authors:  David Burgenson; Chandrasekhar Gurramkonda; Manohar Pilli; Xudong Ge; Abhay Andar; Yordan Kostov; Leah Tolosa; Govind Rao
Journal:  Sci Rep       Date:  2018-06-22       Impact factor: 4.379

10.  On-demand manufacturing of clinical-quality biopharmaceuticals.

Authors:  Laura E Crowell; Amos E Lu; Kerry R Love; Alan Stockdale; Steven M Timmick; Di Wu; Yu Annie Wang; William Doherty; Alexandra Bonnyman; Nicholas Vecchiarello; Chaz Goodwine; Lisa Bradbury; Joseph R Brady; John J Clark; Noelle A Colant; Aleksandar Cvetkovic; Neil C Dalvie; Diana Liu; Yanjun Liu; Craig A Mascarenhas; Catherine B Matthews; Nicholas J Mozdzierz; Kartik A Shah; Shiaw-Lin Wu; William S Hancock; Richard D Braatz; Steven M Cramer; J Christopher Love
Journal:  Nat Biotechnol       Date:  2018-10-01       Impact factor: 54.908
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.